Pharmaceuticals/Chemicals
Mirabegron ER (Myrbetriq)
Also called Mirabegron · Myrbetriq · Betmiga · Betanis
Lifters discuss mirabegron for brown-fat activation and hoped-for fat loss, often comparing it with clenbuterol. The appeal is burning more calories with less nervous energy. Small human studies show metabolic changes, but have not established reliable fat loss.
Dosage & duration
US Myrbetriq extended-release tablet label · adult overactive bladder
Adult OAB starting treatment
Product label- Dose
- 25 mg per dose
- How often
- Once daily by mouth
- How long
- Ongoing treatment; reassess after 4–8 weeks
The label permits an increase to 50 mg daily when appropriate. Kidney/liver impairment and other medicines can limit the dose.
Sources: 2
Swallow the ER tablet whole; do not split, chew or crush it. This is bladder-treatment context, not a brown-fat or fat-loss protocol.
The practical difference
Brown-fat activity versus fat loss
| Question | The hoped-for result | What the evidence shows |
|---|---|---|
| Energy use | Burn more calories | Short-term metabolic changes |
| Body fat | Get leaner during a cut | No weight or fat loss in the small four-week study |
| Clen alternative | Less nervous energy | Feeling different does not prove lower heart or BP risk |
Why is mirabegron on a bodybuilding list?
The appeal is fat loss through a different pathway. Mirabegron stimulates receptors that can activate brown fat—a type of fat that burns energy to produce heat. The practical question is whether that can help a cut without the nervous energy associated with clenbuterol.
Does the brown-fat idea translate into getting leaner?
An acute experiment found increased energy expenditure. A small four-week study also changed brown-fat and metabolic measures, but participants did not lose weight or fat mass. A short-term calorie measurement therefore should not be turned into a forecast of pounds lost.
How do people compare it with clen?
Some people hope for a less stimulating option, but a person who tried it reported no clear fat-loss benefit. That account illustrates uncertainty, not an expected response. Feeling less wired is not a cardiovascular safety test: blood pressure and heart rate can rise with mirabegron.
Why is the dose card about bladder treatment?
That is the established adult prescription context. The experimental metabolic studies do not supply a standard bodybuilding course. Kidney/liver function, interacting medicines and bladder-emptying problems can change suitability, and extended-release tablets should be swallowed whole.
Model details: Mirabegron ER (Myrbetriq) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows timing and dose scaling in relative units, not blood concentrations.
Timing assumptions and sources
Iitsuka 2014 Table 2 Study 2: single fasting 50 mg OCAS tablet in 12 healthy Japanese men, mean terminal half-life 31.9 h and peak time 3.5 h. These source timings are used as a simplified scenario.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 31.9 hours
- Absorption half-life assumed
- 0.5987955 hours
- Reference amount for the relative scale
- 1 mg
- Absorption is inferred to reproduce the stated peak time with the stated terminal rate; this is not a fitted source absorption parameter.
- A single 1 mg input has a peak of 1 relative unit by definition. Repeated-dose addition and linear scaling are mathematical assumptions; the example dose does not calibrate the curve.
- The source curve has a faster distribution phase plus a slow terminal tail. A one-compartment curve cannot match its peak and overall exposure; no absolute amplitude is assigned.
- Actual oral exposure increases more than proportionally with dose. Linear relative scaling is only mathematical and must not be read as a blood-exposure ratio.
- The generic label terminal half-life is about 50 h in patients; that is a different source context and is not mixed into this study-specific timing.
- Food, sex, organ function and formulation affect exposure. This model does not represent immediate-release products or Myrbetriq granules.
- Iitsuka et al. — mirabegron single- and multiple-dose pharmacokinetics
Original 2014 study, Table 2 Study 2: single fasting 50 mg OCAS tablet in 12 healthy Japanese men, mean Cmax 30.1 ng/mL, Tmax 3.5 h, terminal half-life 31.9 h, AUC∞ 275 ng·h/mL. Dose nonlinearity and multiphasic elimination mean a peak/tail one-compartment fit is not an absolute model.
- Astellas/DailyMed — Myrbetriq extended-release tablet label
Astellas label available October 2026 (DailyMed update August 2024, prescribing information revised April 2021): adult overactive bladder 25 mg daily initially, possible 50 mg after 4–8 weeks; swallow whole; blood-pressure/retention precautions; CYP2D6 and digoxin interactions. Oral exposure is more than dose proportional; tablet and granule formulations are not mg-for-mg substitutes.
mirabegron-oral-relative-2026-10 · version 1
Safety and interaction notes Read the limitations and discuss clinical questions with a professional
Monitor blood pressure and review urinary-retention risks. Some interacting medicines require monitoring or adjustment; severe uncontrolled hypertension is a label reason not to use it.
Common questions
Why do bodybuilders use or research mirabegron?
The reported goal is to increase energy expenditure through brown-fat activation, often while looking for an alternative to clenbuterol’s stimulating feel. That goal is documented in community discussions; reliable fat-loss benefit is not established.
Is it a safer version of clenbuterol?
That has not been established. Reports of feeling less wired are not cardiovascular safety comparisons, and mirabegron itself can increase blood pressure and heart rate.
Did the brown-fat studies show weight loss?
The small four-week study reviewed here increased brown-fat activity and other metabolic measures without reducing body weight or fat mass. Acute energy expenditure does not establish a long-term fat-loss result.
Are 25–50 mg the studied bodybuilding doses?
Those numbers in the dose card are the adult bladder-treatment label context. They are not an established bodybuilding regimen. Experimental metabolic studies do not supply a recommended cutting course.
Can I split the extended-release tablet?
No. The label says to swallow it whole without chewing, dividing or crushing.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-09. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Why lifters look at it
- Interest centers on brown-fat activation as another approach to cutting.
- Hoped-for advantage
- This comparison reflects hoped-for and reported effects, not proof of lower cardiovascular risk.
- What is still missing
- A small 4-week study increased metabolic activity without reducing weight or fat mass.
- 1. O’Mara et al. — mirabegron and human brown-fat activity
Original 2020 open-label study in 14 healthy women: 100 mg/day extended-release tablets for 4 weeks (above approved adult OAB maximum). Brown-fat/metabolic measures changed, but body weight and fat mass did not; elevated heart rate/blood pressure and small uncontrolled design limit translation. Not a weight-loss dosing guide.
- 2. Astellas/DailyMed — Myrbetriq extended-release tablet label
Astellas label available October 2026 (DailyMed update August 2024, prescribing information revised April 2021): adult overactive bladder 25 mg daily initially, possible 50 mg after 4–8 weeks; swallow whole; blood-pressure/retention precautions; CYP2D6 and digoxin interactions. Oral exposure is more than dose proportional; tablet and granule formulations are not mg-for-mg substitutes.
- 3. Cypess et al. — activation of human brown adipose tissue
Original 2015 acute study: 12 men with detectable brown fat; 200 mg oral mirabegron versus placebo. Demonstrates research rationale, not a safe or effective long-term fat-loss regimen.
- 4. Iitsuka et al. — mirabegron single- and multiple-dose pharmacokinetics
Original 2014 study, Table 2 Study 2: single fasting 50 mg OCAS tablet in 12 healthy Japanese men, mean Cmax 30.1 ng/mL, Tmax 3.5 h, terminal half-life 31.9 h, AUC∞ 275 ng·h/mL. Dose nonlinearity and multiphasic elimination mean a peak/tail one-compartment fit is not an absolute model.
Related compounds and examples
Related compounds
Estradiol Topical (EstroGel)
Estradiol gel is used to ease menopausal hot flushes and other low-estrogen symptoms without a pill or injection. The practical choices are the exact pump product, the daily skin routine and whether a separate progestogen is needed.
Estradiol Cypionate
Estradiol cypionate provides estrogen through an injection rather than a daily pill or gel. It is used for low-estrogen symptoms and in feminizing hormone care; the reason for treatment determines the dose and schedule.
Estradiol Valerate
Estradiol valerate injections are used for estrogen replacement and feminizing hormone care. Readers usually want a manageable injection routine and fewer swings between doses. The amount, interval and reason for treatment matter more than chasing a high peak.